Arulparithi Cuddalore Subramanian, Babu Thirunavukkarasu Arun, Ravichandran C, Santhanam Indumathy, Sathyamurthi B, Parivathini S, Hemachitra J
Department of Pediatrics, Karpaga Vinayaga Institute of Medical Sciences, Maduranthagam, Tamil Nadu, India.
Indian J Pediatr. 2015 Apr;82(4):328-32. doi: 10.1007/s12098-014-1498-0. Epub 2014 Jun 7.
To compare the efficacy of nebulised budesonide with that of oral prednisone in the treatment of acute severe asthma in children.
Children aged 5-12 y with acute exacerbation of bronchial asthma were included. The study (budesonide) group received budesonide respirator solution (800 μg) at intervals of 20 min and a single dose of placebo tablets. The control (prednisolone) group received placebo solution at intervals of 20 min and a single dose of oral prednisolone (2 mg/kg). Both groups received three doses of nebulised salbutamol (0.15 mg/kg). Heart rate, respiratory rate, oxygen saturation, PEFR (Peak Expiratory Flow Rate) and fitness for discharge were assessed.
Both groups showed a progressive decrease in tachycardia with treatment, but it was significantly greater in study group (p = 0.0002). There was significant decrease in tachypnea and improvement in oxygen saturation in both groups, but the difference between the groups (p = 0.334 and p = 0.814 respectively) was not significant. There was significant improvement in PEFR values in budesonide group (p = 0.024). Both groups showed significant improvement in clinical severity scores at the end of 2 h (p < 0.0001). Budesonide group had significantly higher proportion of patients fit for discharge at 2 h (based on clinical severity scores) (p = 0.0278).
Nebulised budesonide significantly improves PEFR levels and fitness for discharge at 2 h when compared to oral prednisolone in children between 5 and 12 y with acute severe asthma.
比较雾化布地奈德与口服泼尼松治疗儿童急性重度哮喘的疗效。
纳入5至12岁支气管哮喘急性加重期的儿童。研究(布地奈德)组每隔20分钟接受一次布地奈德雾化液(800μg)及单剂安慰剂片。对照组(泼尼松龙)组每隔20分钟接受一次安慰剂溶液及单剂口服泼尼松龙(2mg/kg)。两组均接受三剂雾化沙丁胺醇(0.15mg/kg)。评估心率、呼吸频率、血氧饱和度、呼气峰值流速(PEFR)及出院适宜度。
两组治疗后心动过速均逐渐减轻,但研究组减轻更为显著(p = 0.0002)。两组呼吸急促均显著减轻,血氧饱和度均有所改善,但组间差异不显著(分别为p = 0.334和p = 0.814)。布地奈德组的PEFR值有显著改善(p = 0.024)。两组在2小时末临床严重程度评分均有显著改善(p < 0.0001)。布地奈德组在2小时时(基于临床严重程度评分)适合出院的患者比例显著更高(p = 0.0278)。
对于5至12岁急性重度哮喘儿童,与口服泼尼松龙相比,雾化布地奈德在2小时时能显著提高PEFR水平及出院适宜度。